Physician profile
Elliot L Plotkin
NPI 1386664084
$5,160.48
in general payments reported to CMS, 2019-2025
33 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $752 · 2021: $924 · 2022: $778 · 2023: $943 · 2024: $703 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,613.84 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $446.10 | 2021-2024 | |
| Biotissue Holdings INC. | $382.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $274.60 | 2020-2022 | |
| Smith+Nephew, INC. | $214.16 | 2019-2022 | |
| Janssen Biotech, INC. | $157.66 | 2022-2025 | Tremfya |
| Medline Industries LP | $154.35 | 2023 | |
| Depuy Synthes Sales INC. | $128.70 | 2024-2025 | Na |
| Paratek Pharmaceuticals, INC. | $89.04 | 2024-2025 | Nuzyra |
| Lilly USA, LLC | $70.96 | 2019-2020 | |
| Stryker Corporation | $65.15 | 2020 | |
| Merck Sharp & Dohme LLC | $61.19 | 2019-2020 | |
| Celgene Corporation | $44.10 | 2019 | |
| Treace Medical Concepts, INC. | $40.52 | 2022 | |
| Wright Medical Technology, INC. | $39.72 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $37.57 | 2024 | Physio-Stim, Accelstim |
| Ucb, INC. | $30.76 | 2024 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $26.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.77 | 2020 | |
| Cardiovascular Systems INC. | $24.54 | 2020 | |
| Ani Pharmaceuticals, INC. | $23.30 | 2024 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $22.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2022 | |
| Zimmer Biomet Holdings, INC. | $20.23 | 2021 | |
| Abbvie INC. | $20.08 | 2024 | |
| Paragon 28, INC. | $19.60 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.17 | 2023 | Lupkynis |
| Amniox Medical, INC. | $16.60 | 2020 | |
| Bsn Medical INC | $15.95 | 2022 | |
| Mimedx Group, INC. | $15.40 | 2024 | |
| Averitas Pharma INC. | $15.09 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.38 | 2019 | |
| Medartis INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Plotkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.